All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @bajandriver973 on TikTok · 80s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @bajandriver973's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00There's an update, what, 28, 32 hours later the next day.
  2. 0:07I was tired yesterday.
  3. 0:13I'm even more tired today.
  4. 0:16I called myself trying to make dinner last night for the family.
  5. 0:22That, that had me so exhausted.
  6. 0:26And then I made wings, went like mashed potatoes and asparagus.
  7. 0:34I ate like a spoon, one spoon full of mac and mashed potatoes.
  8. 0:43And I had like three wingnuts.
  9. 0:46That was it.
  10. 0:48I took the rice for lunch today and I took my lunch out to Fidgevade.
  11. 0:52I'm like, I just have no appetite, no desire to eat.
  12. 0:57But I'm also very, very, very tired and tired.
  13. 1:01I don't got no energy right now.
  14. 1:05This is weird, but a small update.
  15. 1:09I'm 7.5.
  16. 1:11I got no appetite.
  17. 1:14First couple days, you know, I got no energy.

@bajandriver973's Zepbound fatigue claims, fact-checked

Life of Sosa

TikTok creator

104.2K viewsWatch on TikTok

Quick answer

The creator is approximately 28 to 32 hours post-injection on tirzepatide 7.5mg and reporting significant fatigue alongside near-total appetite suppression, eating fewer than 300 estimated calories in the described period. This presentation is consistent with early post-injection GIP/GLP-1 dual agonist effects combined with secondary fatigue from acute caloric restriction, both of which are documented in the SURMOUNT trial adverse event profiles. Fatigue of this type typically peaks within the first two to three days post-injection and is expected to diminish as the patient adapts to the dose over the four-week escalation window.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @bajandriver973's Zepbound fatigue claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@bajandriver973's Zepbound fatigue claims, fact-checked" from Life of Sosa. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is approximately 28 to 32 hours post-injection on tirzepatide 7.

The reason this review is not generic is the source wording and the canonical claim label "glp1 this 7 5mg is by far the worse dose as far as having no ener." In this clip, the useful excerpt is: "There's an update, what, 28, 32 hours later the next day." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tirzepatide's half-life is approximately five days per Eli Lilly's 2023 prescribing information, meaning peak plasma concentration aligns with the day-one to day-two fatigue window this creator describes.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is approximately 28 to 32 hours post-injection on tirzepatide 7.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is approximately 28 to 32 hours post-injection on tirzepatide 7.5mg and reporting significant fatigue alongside near-total appetite suppression, eating fewer than 300 estimated calories in the described period. This presentation is consistent with early post-injection GIP/GLP-1 dual agonist effects combined with secondary fatigue from acute caloric restriction, both of which are documented in the SURMOUNT trial adverse event profiles. Fatigue of this type typically peaks within the first two to three days post-injection and is expected to diminish as the patient adapts to the dose over the four-week escalation window.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) reported fatigue in 9 to 13 percent of tirzepatide participants, with rates highest during dose escalation windows, not at maintenance.
  • Tirzepatide's half-life is approximately five days per Eli Lilly's 2023 prescribing information, meaning peak plasma concentration aligns with the day-one to day-two fatigue window this creator describes.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) reported fatigue in 9 to 13 percent of tirzepatide participants, with rates highest during dose escalation windows, not at maintenance.
  • Tirzepatide's half-life is approximately five days per Eli Lilly's 2023 prescribing information, meaning peak plasma concentration aligns with the day-one to day-two fatigue window this creator describes.
  • A 2023 Diabetes Care analysis found tirzepatide produces direct central nervous system effects on energy regulation via hypothalamic GIP and GLP-1 receptors, not just fatigue secondary to nausea or vomiting.
  • Eating almost nothing compounds medication-related fatigue. Acute caloric restriction independently causes low energy, and separating those two effects is difficult without tracking intake carefully.
  • Early post-injection side effects at a new dose are expected to ease over the four-week period before the next escalation step. Predicting long-term serious suppression based on 28 to 32 hours of data is premature.
  • Individual response to each tirzepatide dose varies substantially. Some patients report worse side effects at lower doses due to GI sensitivity; others tolerate 7.5mg better than 5mg.
  • If severe fatigue persists beyond day four or five after injection, that warrants a conversation with a prescriber rather than self-management based on social media timelines.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @bajandriver973 actually say?

Roughly 28 to 32 hours after injecting tirzepatide 7.5mg, this creator described being so exhausted that cooking dinner "had me so exhausted" and eating almost nothing, just a spoonful of mashed potatoes and three wings. They're connecting the fatigue directly to the dose increase, calling it their worst dose yet for energy and predicting "serious" appetite suppression going forward.

To be clear about what they're actually claiming: dose-dependent fatigue, dramatic appetite loss in the first days post-injection, and a sense that 7.5mg hits differently than lower doses. Those are distinct claims and they deserve to be evaluated separately, because some hold up better than others.

Does the science back this up?

Fatigue after a tirzepatide dose increase is real and documented. Yes, the science backs the core observation, though the mechanism is more complicated than most TikTok content suggests.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) tracked adverse events across the tirzepatide dose escalation schedule, and fatigue was reported in roughly 9 to 13 percent of participants, with rates tending to cluster around dose escalation windows. More relevant here, a 2023 pharmacodynamic analysis published in Diabetes Care (Rosenstock et al.) found that GIP and GLP-1 dual agonism produces stronger central nervous system effects than GLP-1 alone, including effects on energy regulation in the hypothalamus. That's not just nausea making you tired. There appears to be a direct CNS component. Separately, acute caloric restriction, which is exactly what this creator is experiencing, is itself a driver of fatigue. When you eat one spoonful of mashed potatoes and three wings in a day, your body notices.

What did they get wrong (or right)?

They got the fatigue observation right. Where they overstep is the word "suppression," which implies a sustained, serious clinical effect rather than a transient dose-escalation response.

The available data suggests most patients see fatigue peak in the first one to three days post-injection and then ease as the week progresses. Reporting from the SURMOUNT program consistently showed that GI and energy-related side effects were most pronounced during the escalation phase, not at maintenance doses. If this creator is still exhausted by day seven or eight, that's worth a call to their prescriber. But predicting "serious suppression" as a baseline expectation for 7.5mg overstates the evidence. It also risks discouraging other patients who might tolerate this dose fine. To give credit: the observation that appetite vanished faster than energy did is actually consistent with how tirzepatide works. Appetite suppression via GLP-1 and GIP receptor activity can precede the body's adaptation to lower caloric intake, which is probably why fatigue hits harder than expected early on.

What should you actually know?

If you're escalating to 7.5mg and you feel wrecked for the first two or three days, that is not unusual. It is also not a reason to panic or assume the drug is failing you.

There are a few practical things worth knowing. First, the fatigue loop here is partly self-reinforcing: the drug suppresses appetite, you eat almost nothing, low caloric intake worsens fatigue, and then you attribute all of it to the medication. Both things are true at once. Second, tirzepatide's half-life is approximately five days (Eli Lilly prescribing information, 2023), meaning peak plasma levels occur a day or two post-injection, which lines up with when this creator felt worst. Third, individual variability in response is significant. Not everyone hits a wall at 7.5mg. Some patients report the opposite, actually feeling more energy once nausea from lower doses resolves. This video captures one person's experience on one day. Treat it accordingly, not as a forecast for your own treatment.

  • Eat something, even small amounts, to avoid compounding medication fatigue with caloric-deficit fatigue.
  • Track fatigue day by day across your injection week, not just in the first 48 hours.
  • If fatigue is severe or lasts beyond day four or five post-injection, contact your prescriber. It may warrant a dose adjustment or timeline change.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Life of Sosa · TikTok creator

104.2K views on this video

This 7.5mg is by far the worse dose as far as having no energy. I feel the suppression will be SERIOUS on this dose. #zepbound #zepboundjourney

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) reported fatigue in 9?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) reported fatigue in 9 to 13 percent of tirzepatide participants, with rates highest during dose escalation windows, not at maintenance.

What does the video say about tirzepatide's half-life?

Tirzepatide's half-life is approximately five days per Eli Lilly's 2023 prescribing information, meaning peak plasma concentration aligns with the day-one to day-two fatigue window this creator describes.

What does the video say about a 2023 diabetes care analysis found tirzepatide produces direct central?

A 2023 Diabetes Care analysis found tirzepatide produces direct central nervous system effects on energy regulation via hypothalamic GIP and GLP-1 receptors, not just fatigue secondary to nausea or vomiting.

What does the video say about eating almost nothing compounds medication-related fatigue. acute caloric restriction independently?

Eating almost nothing compounds medication-related fatigue. Acute caloric restriction independently causes low energy, and separating those two effects is difficult without tracking intake carefully.

What does the video say about early post-injection side effects at a new dose?

Early post-injection side effects at a new dose are expected to ease over the four-week period before the next escalation step. Predicting long-term serious suppression based on 28 to 32 hours of data is premature.

What does the video say about individual response to each tirzepatide dose varies substantially. some patients?

Individual response to each tirzepatide dose varies substantially. Some patients report worse side effects at lower doses due to GI sensitivity; others tolerate 7.5mg better than 5mg.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Life of Sosa, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.